The value and limitation of iloprost infusion in decreasing skeletal muscle necrosis.
Iloprost has been shown to minimize skeletal muscle necrosis when administered before the onset of ischemia in animal experiments, possibly by preventing neutrophil activation. Since patients with acute limb ischemia are seen after the process has begun, we investigated whether iloprost can be protective when given only during reperfusion. After anesthesia, 18 adult mongrel dogs underwent a standard isolated gracilis muscle preparation. In six control animals (group I) the gracilis muscle was subjected to 6 hours of ischemia followed by 48 hours of reperfusion. Group II animals (n = 6) received intravenous infusion of iloprost at a dose of 0.45 microgram/kg/hr beginning 1 hour before the onset of muscle ischemia and throughout the experiment (6 hours of ischemia and 1 hour of reperfusion). In addition to the continuous infusion, they received 0.45 microgram/kg intravenous boluses of iloprost 10 minutes before the induction of ischemia and 10 minutes before reperfusion. Group III animals (n = 6) had a similar ischemic interval, but were given a bolus of iloprost of 0.45 microgram/kg at end ischemia followed by continuous infusion of 0.45 microgram/kg/hr for 48 hours during reperfusion. Muscle biopsies were obtained at baseline and after 1 hour of reperfusion in all groups. Additional biopsies were obtained at 48 hours of reperfusion in groups I and III. Myeloperoxidase activity, a marker of neutrophil activation, was measured in all muscle biopsies. At the end of reperfusion, the gracilis muscle was harvested in all animals and weighed. Muscle necrosis was estimated by serial transection, nitroblue tetrazolium histochemical staining followed by computerized planimetry.(ABSTRACT TRUNCATED AT 250 WORDS)
Mohan
C
C
Division of Vascular Surgery, Maimonides Medical Center, Brooklyn, NY 11219.
Marini
C
C
Gennaro
M
M
Ascer
E
E
D000704:Analysis of Variance; D000818:Animals; D004285:Dogs; D016285:Iloprost / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D009132:Muscles / Q000098:blood supply / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D009336:Necrosis / Q000517:prevention & control; D009504:Neutrophils / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D015427:Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors
D009195:Peroxidase; D016285:Iloprost